Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges
Source abstract
Abstract
Abstract Bifunctional proteins (BFPs) are a class of therapeutic agents produced through genetic engineering and protein engineering, and are increasingly used to treat various human diseases, including cancer. These proteins usually have two or more biological functions—specifically recognizing different molecular targets to regulate the related signaling pathways, or mediating effector molecules/cells to kill tumor cells. Unlike conventional small‐molecule or single‐target drugs, BFPs possess stronger biological activity but lower systemic toxicity. Hence, BFPs are considered to offer many benefits for the treatment of heterogeneous tumors. In this review, the authors briefly describe the unique structural feature of BFP molecules and innovatively divide them into bispecific antibodies, cytokine‐based BFPs (immunocytokines), and protein toxin‐based BFPs (immunotoxins) according to their mode of action. In addition, the latest advances in the development of BFPs are discussed and the potential limitations or problems in clinical applications are outlined. Taken together, future studies need to be centered on understanding the characteristics of BFPs for optimizing and designing more effective such drugs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · Toxin Mechanisms and Immunotoxins · CAR-T cell therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmacy The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan 450052 China
Laboratory of Molecular Biology Center for Cancer Research National Institutes of Health Bethesda MD 20892 USA
Funding
National Natural Science Foundation of China
References (100+)
Show source-provided references
1. 10.1038/nrclinonc.2017.16610.1038/nrclinonc.2017.166 ↗
2. 10.3322/caac.2166010.3322/caac.21660 ↗
3. 10.1016/j.jconrel.2017.02.00610.1016/j.jconrel.2017.02.006 ↗
4. 10.1038/s41571-018-0046-710.1038/s41571-018-0046-7 ↗
5. 10.1007/s13238-016-0323-010.1007/s13238-016-0323-0 ↗
6. 10.3389/fonc.2018.0017310.3389/fonc.2018.00173 ↗
7. 10.1038/s41581-018-0035-110.1038/s41581-018-0035-1 ↗
8. 10.1016/j.pharmthera.2017.12.00210.1016/j.pharmthera.2017.12.002 ↗
9. 10.1016/j.pharmthera.2017.07.01310.1016/j.pharmthera.2017.07.013 ↗
10. 10.1038/nrc323610.1038/nrc3236 ↗
11. 10.1038/nrclinonc.2014.15910.1038/nrclinonc.2014.159 ↗
12. 10.1038/nrd.2017.22710.1038/nrd.2017.227 ↗
13. 10.1007/s40264-015-0285-910.1007/s40264-015-0285-9 ↗
14. 10.1016/j.compbiomed.2016.06.01510.1016/j.compbiomed.2016.06.015 ↗
15. 10.1016/j.biotechadv.2014.11.00510.1016/j.biotechadv.2014.11.005 ↗
16. 10.1016/j.tibtech.2014.11.00110.1016/j.tibtech.2014.11.001 ↗
17. 10.1016/j.addr.2012.09.03910.1016/j.addr.2012.09.039 ↗
18. 10.1016/j.pnsc.2008.12.00710.1016/j.pnsc.2008.12.007 ↗
19. 10.4238/2015.December.29.4610.4238/2015.December.29.46 ↗
20. 10.2147/DDDT.S15128210.2147/DDDT.S151282 ↗
21. 10.1016/S1389-0344(01)00083-110.1016/S1389-0344(01)00083-1 ↗
22. 10.1186/s40164-017-0072-710.1186/s40164-017-0072-7 ↗
23. 10.1016/j.drudis.2015.02.00810.1016/j.drudis.2015.02.008 ↗
24. Graziano R. F. · 2004 · 7110.1385/1-59259-813-7:071 ↗
25. 10.1016/j.ctrv.2010.03.00110.1016/j.ctrv.2010.03.001 ↗
26. 10.1016/j.ddtec.2018.09.00310.1016/j.ddtec.2018.09.003 ↗
27. 10.4161/mabs.1.6.1001510.4161/mabs.1.6.10015 ↗
28. 10.4161/mabs.4.2.1900010.4161/mabs.4.2.19000 ↗
29. 10.1186/s13045-015-0227-010.1186/s13045-015-0227-0 ↗
30. 10.1155/2019/451604110.1155/2019/4516041 ↗
31. 10.1080/13543776.2018.142830710.1080/13543776.2018.1428307 ↗
32. 10.1038/s41573-019-0028-110.1038/s41573-019-0028-1 ↗
33. 10.4161/mabs.1.4.875510.4161/mabs.1.4.8755 ↗
34. 10.1038/nri276110.1038/nri2761 ↗
35. 10.4049/jimmunol.155.1.21910.4049/jimmunol.155.1.219 ↗
36. 10.4161/mabs.2.3.1179110.4161/mabs.2.3.11791 ↗
37. 10.2217/fon.11.13810.2217/fon.11.138 ↗
38. 10.1111/bjh.1324210.1111/bjh.13242 ↗
39. 10.1517/13543784.17.10.155310.1517/13543784.17.10.1553 ↗
40. 10.1093/protein/9.7.61710.1093/protein/9.7.617 ↗
41. 10.1006/jmbi.1997.111610.1006/jmbi.1997.1116 ↗
42. 10.1186/1753-6561-7-S6-O910.1186/1753-6561-7-S6-O9 ↗
43. 10.1200/JCO.2018.36.5_suppl.TPS8110.1200/JCO.2018.36.5_suppl.TPS81 ↗
44. 10.1074/jbc.M110.11738210.1074/jbc.M110.117382 ↗
45. 10.1016/j.ymeth.2018.10.00510.1016/j.ymeth.2018.10.005 ↗
46. 10.1007/s40495-017-0090-510.1007/s40495-017-0090-5 ↗
47. 10.4161/mabs.2563210.4161/mabs.25632 ↗
48. 10.1182/blood-2018-99-11978610.1182/blood-2018-99-119786 ↗
49. 10.1080/19420862.2016.119745710.1080/19420862.2016.1197457 ↗
50. 10.1016/j.pharmthera.2019.04.00610.1016/j.pharmthera.2019.04.006 ↗
51. 10.1200/JCO.2017.35.15_suppl.353910.1200/JCO.2017.35.15_suppl.3539 ↗
52. 10.1080/19420862.2016.116019210.1080/19420862.2016.1160192 ↗
53. 10.1182/blood-2020-13634410.1182/blood-2020-136344 ↗
54. 10.1038/nbt.279710.1038/nbt.2797 ↗
55. 10.1080/19420862.2015.100781610.1080/19420862.2015.1007816 ↗
56. 10.4161/mabs.2397710.4161/mabs.23977 ↗
57. 10.1007/978-1-61779-921-1_910.1007/978-1-61779-921-1_9 ↗
58. 10.1038/nbt134510.1038/nbt1345 ↗
59. 10.1158/1535-7163.MCT-17-080010.1158/1535-7163.MCT-17-0800 ↗
60. 10.1016/j.cbpa.2013.04.01510.1016/j.cbpa.2013.04.015 ↗
61. 10.1158/1078-0432.CCR-17-064610.1158/1078-0432.CCR-17-0646 ↗
62. 10.3389/fonc.2016.0023210.3389/fonc.2016.00232 ↗
63. 10.1007/s40262-016-0405-410.1007/s40262-016-0405-4 ↗
64. 10.1016/j.copbio.2011.06.01210.1016/j.copbio.2011.06.012 ↗
65. 10.1016/B978-0-12-386483-3.00004-510.1016/B978-0-12-386483-3.00004-5 ↗
66. 10.1158/0008-5472.CAN-09-054710.1158/0008-5472.CAN-09-0547 ↗
67. Han M. · University of Southern California, M.Sc. · 2016
68. 10.1182/blood-2010-09-30644910.1182/blood-2010-09-306449 ↗
69. 10.1182/blood-2014-05-57570410.1182/blood-2014-05-575704 ↗
70. 10.2217/fon.12.5410.2217/fon.12.54 ↗
71. 10.1200/JCO.2020.38.15_suppl.TPS314810.1200/JCO.2020.38.15_suppl.TPS3148 ↗
72. 10.4161/onci.2289110.4161/onci.22891 ↗
73. 10.1200/JCO.2017.35.15_suppl.953110.1200/JCO.2017.35.15_suppl.9531 ↗
74. 10.1016/j.chembiol.2006.12.00310.1016/j.chembiol.2006.12.003 ↗
75. 10.3389/fimmu.2017.0160310.3389/fimmu.2017.01603 ↗
76. C.Le Tourneau R.Claus F.Ricci B.Hackanson C.Rummelt O.Fietz T.Arnhold D.Roy Z.Oum'Hamed R.Fritsch Presented at the American Society of Clinical Oncology Annual Meeting Chicago IL USA June2018.
77. 10.1038/nrc125210.1038/nrc1252 ↗
78. 10.1016/j.coi.2016.03.00610.1016/j.coi.2016.03.006 ↗
79. 10.1007/978-3-0348-8346-7_610.1007/978-3-0348-8346-7_6 ↗
80. Gillies S. D. · Cancer Res. · 1999 · 59 · 2159
81. 10.1074/jbc.M21066520010.1074/jbc.M210665200 ↗
82. 10.1016/j.nbt.2019.04.00210.1016/j.nbt.2019.04.002 ↗
83. 10.1016/j.addr.2018.09.00210.1016/j.addr.2018.09.002 ↗
84. 10.1093/protein/gzt04510.1093/protein/gzt045 ↗
85. 10.1158/1078-0432.CCR-05-221710.1158/1078-0432.CCR-05-2217 ↗
86. 10.1016/1380-2933(95)00027-510.1016/1380-2933(95)00027-5 ↗
87. 10.1016/j.jbiotec.2018.12.00410.1016/j.jbiotec.2018.12.004 ↗
88. 10.1016/j.xphs.2019.10.03710.1016/j.xphs.2019.10.037 ↗
89. 10.1016/0092-8674(86)90506-410.1016/0092-8674(86)90506-4 ↗
90. 10.1177/101042831769222610.1177/1010428317692226 ↗
91. 10.1016/S0952-7915(99)00005-910.1016/S0952-7915(99)00005-9 ↗
92. 10.1080/08830185.2017.128421110.1080/08830185.2017.1284211 ↗
93. 10.1208/aapsj08036310.1208/aapsj080363 ↗
94. 10.1111/j.1349-7006.2009.01192.x10.1111/j.1349-7006.2009.01192.x ↗
95. 10.1097/CAD.000000000000045210.1097/CAD.0000000000000452 ↗
96. 10.1016/j.ymeth.2005.01.00110.1016/j.ymeth.2005.01.001 ↗
97. 10.1055/s-0039-170050710.1055/s-0039-1700507 ↗
98. 10.1016/j.drudis.2011.04.00310.1016/j.drudis.2011.04.003 ↗
99. 10.1517/1471259090334813510.1517/14712590903348135 ↗
100. 10.1007/s40265-019-01087-z10.1007/s40265-019-01087-z ↗